My ePortfolio Register   

ESGO 2011 /
Treating cancer during pregnancy

11th - 14th Sep 2011

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.10.11
Views: 4457
Rating:

Dr Frederic Amant – Katholieke Universiteit, Leuven, Belgium

At ESGO 2011, Dr Frederic Amant presented preliminary data on the first study since 2004 to deal with cancer and pregnancy. His study began when a cervical cancer patient wanted to keep the pregnancy during her treatment. The overall aims of the study are to fill the large gaps in data on treating cancer patients during pregnancy. Thus far study has been able to identify the percentages of occurrence during pregnancy in each type of cancer.

At the moment, more than 50% of specialists prefer to terminate pregnancies or to have preterm delivery in order to administer treatment rather than treat with chemotherapy; however, preliminary data shows that the placenta acts as a filter for most types of chemotherapy. In fact, it is safe after the 1st trimester to administer treatment, but there is a need for extended data. Dr Amant also discusses the difficulties and differences between treating breast and cervical cancer patients and how treatment depends on the patient’s wishes, stage of treatment and stage of pregnancy.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence